Redifferentiation therapy prior to radioiodine in refractory differentiated thyroid cancer: A systematic review and meta-analysis
Background: Radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) has a poor prognosis. Constitutive MAPK activation, frequently driven by BRAF V600E or RAS alterations, suppresses thyroid-specific genes and sodium-iodide symporter expression. Short-course BRAF and/or MEK inhibition before RAI aims to restor...